Medical Gas Research最新文献

{"title":"Respiratory frequency: from health to sports performance monitoring.","authors":"Adriano Di Paco, Roberto Cannataro","doi":"10.4103/mgr.MEDGASRES-D-24-00134","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00134","url":null,"abstract":"","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"15 2","pages":"218-219"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential therapeutic applications of medical gases in cancer treatment.","authors":"Abbas Al Bazzal, Bassel H Hoteit, Mariam Chokor, Abdallah Safawi, Zahraa Zibara, Fatima Rizk, Aya Kawssan, Naseeb Danaf, Layal Msheik, Hiba Hamdar","doi":"10.4103/mgr.MEDGASRES-D-24-00089","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00089","url":null,"abstract":"<p><p>Medical gases were primarily used for respiratory therapy and anesthesia, which showed promising potential in the cancer therapy. Several physiological and pathological processes were affected by the key gases, such as oxygen, carbon dioxide, nitric oxide, hydrogen sulfide, and carbon monoxide. Oxygen targets shrinking the tumor via hyperbaric oxygen therapy, and once combined with radiation therapy it enhances its effect. Nitric oxide has both anti- and pro-tumor effects depending on its level; at high doses, it triggers cell death while at low doses it supports cancer growth. The same concept is applied to hydrogen sulfide which promotes cancer growth by enhancing mitochondrial bioenergetics and supporting angiogenesis at low concentrations, while at high concentrations it induces cancer cell death while sparing normal cells. Furthermore, carbon dioxide helps induce apoptosis and improve oxygenation for cancer treatments by increasing the release of oxygen from hemoglobin. Moreover, high-dose carbon monoxide gas therapy has demonstrated significant tumor reductions in vivo and is supported by nanomedicine and specialized medicines to boost its delivery to tumor cells and the availability of hydrogen peroxide. Despite the promising potentials of these gases, several challenges remain. Gas concentrations should be regulated to balance pro-tumor and anti-tumor effects for gases such as nitric oxide and hydrogen sulfide. Furthermore, effective delivery systems, such as nanoparticles, should be developed for targeted therapy.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"15 2","pages":"309-317"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Piezocatalysis for gas generation and disease therapy.","authors":"Qinyu Zhao, Songjing Zhong, Linlin Li","doi":"10.4103/mgr.MEDGADRES-D-24-00105","DOIUrl":"10.4103/mgr.MEDGADRES-D-24-00105","url":null,"abstract":"","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"15 2","pages":"202-203"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing extracorporeal carbon dioxide removal technology: bridging basic science and clinical practice.","authors":"Sergio Lassola, Denise Battaglini, Silvia De Rosa","doi":"10.4103/mgr.MEDGASRES-D-24-00051","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00051","url":null,"abstract":"<p><p>Recently, advancements in extracorporeal carbon dioxide removal (ECCO 2 R) technology have markedly enhanced its clinical applicability and efficacy for managing severe respiratory conditions. This review highlights critical innovations in ECCO 2 R, such as advanced catheter technologies, active mixing methods, and biochemical enhancements, which have substantially improved gas exchange efficiency and broadened the scope of ECCO 2 R applications. Integrating ECCO 2 R into acute and chronic respiratory care has led to a shift toward more mobile and less invasive modalities, promising for extending ECCO 2 R usage from intensive care units to home settings. By examining these technological advancements and their clinical impacts, this paper outlines the potential future directions of ECCO 2 R technology, emphasizing its role in transforming respiratory care practices and enhancing patient outcomes.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":" ","pages":"288-298"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperbaric oxygen therapy for cardiovascular surgery.","authors":"Dongchenlei Wang, Mo Liu, Shaoting Jia, Zichuan Tian, Jing Yang, Xuehua Liu","doi":"10.4103/mgr.MEDGASRES-D-24-00095","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00095","url":null,"abstract":"<p><p>Common cardiovascular surgeries include coronary artery bypass grafting, cardiac valve replacement, radiofrequency ablation, and cardiac intervention surgery. Multiple postoperative complications, such as hypoxic encephalopathy, air embolism, retained intracardiac air, cognitive dysfunction and major adverse cardiovascular events, including heart failure, ischemic stroke, and myocardial infarction, may occur after these cardiovascular surgeries. Hyperbaric oxygen can be used in preconditioning to lower the morbidity of adverse complications. It is also effective for the treatment of numerous postoperative complications. We provide evidence from the current literature highlighting the use of hyperbaric oxygen therapy for preconditioning and managing postoperative complications.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"15 2","pages":"299-308"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperbaric oxygen therapy for paroxysmal sympathetic hyperactivity syndrome after brain injury: a multicenter, retrospective cohort study.","authors":"Hong Wang, Yujing Li, Songying Shen, Xin Li, Changhe Li, Yihao Li, Huimin Chen, Caihong Ren, Yinsen Song, Yao Tang, Huijun Dong, Meng Zhao, Sisen Zhang, Hongyu Wang","doi":"10.4103/mgr.MEDGASRES-D-24-00077","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00077","url":null,"abstract":"<p><p>Hyperbaric oxygen has been used to treat many diseases. However, there are few reports on hyperbaric oxygen treatment for paroxysmal sympathetic hyperactivity at home and abroad, and the clinical experience is very limited. To understand the efficacy of hyperbaric oxygen treatment for paroxysmal sympathetic hyperactivity after brain injury, this retrospective study was conducted in the adult intensive care units of five medical centers in central China. Ninety-two patients with paroxysmal sympathetic hyperactivity syndrome after brain injury were selected from January 2021 to September 2023. Fifty-six patients treated with hyperbaric oxygen were included in the hyperbaric oxygen group, and 36 patients without hyperbaric oxygen treatment were included in the control group. Patients in the hyperbaric oxygen group received 3-5 courses of hyperbaric oxygen treatment, twice daily, once for 70 minutes, 10 days for 1 course of treatment. Compared with before hyperbaric oxygen treatment, the paroxysmal sympathetic hyperactivity symptoms of all patients were significantly relieved after three courses of hyperbaric oxygen treatment. Compared with those in the control group, patients in the hyperbaric oxygen group had higher Glasgow coma scale scores, lower paroxysmal sympathetic hyperactivity syndrome assessment measure scores, and shorter intensive care unit stays. In conclusion, the use of hyperbaric oxygen therapy as an assisted therapy can significantly alleviate the symptoms of patients with paroxysmal sympathetic hyperactivity, thereby providing new ideas for the treatment of paroxysmal sympathetic hyperactivity.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"15 2","pages":"327-331"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in medical gas sensing with artificial intelligence-enabled technology.","authors":"Chitaranjan Mahapatra","doi":"10.4103/mgr.MEDGASRES-D-24-00113","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00113","url":null,"abstract":"<p><p>Recent advancements in artificial intelligence-enabled medical gas sensing have led to enhanced accuracy, safety, and efficiency in healthcare. Medical gases, including oxygen, nitrous oxide, and carbon dioxide, are essential for various treatments but pose health risks if improperly managed. This review highlights the integration of artificial intelligence in medical gas sensing, enhancing traditional sensors through advanced data processing, pattern recognition, and real-time monitoring capabilities. Artificial intelligence improves the ability to detect harmful gas levels, enabling immediate intervention to prevent adverse health effects. Moreover, developments in nanotechnology have resulted in advanced materials, such as metal oxides and carbon-based nanomaterials, which increase sensitivity and selectivity. These innovations, combined with artificial intelligence, support continuous patient monitoring and predictive diagnostics, paving the way for future breakthroughs in medical care.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"15 2","pages":"318-326"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918459/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a high inspired oxygen fraction on oxidative stress in pediatric patients: reassuring results based on a randomized trial.","authors":"Ting Li, Ying Han, Xiaodie Zhang, Jialian Zhao, Yaojun Suo, Yaoqin Hu","doi":"10.4103/mgr.MEDGASRES-D-24-00073","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00073","url":null,"abstract":"<p><p>High-concentration oxygen inhalation is the primary intervention to prevent perioperative hypoxemia. However, there are concerns that this may induce an imbalance in oxidation‒reduction processes, particularly in pediatric patients with compromised antioxidant defenses. This study aimed to evaluate the impact of varying intraoperative concentrations of oxygen inhalation on oxidative stress in children by analyzing plasma biomarkers, oxygenation indices, and the duration of surgery and oxygen inhalation. Forty-five children scheduled for laparoscopic pyeloplasty under general anesthesia were randomly assigned to three groups, each receiving different fractions of inspired oxygen during surgery: 30%, 50%, or 80%. The primary outcome was the plasma concentration of oxidative stress markers, and the other measurements included the surgical duration and duration of oxygen exposure. Thirty-five children completed the study, with 11 in the low group, 12 in the medium group and 12 in the high group. The levels of superoxide dismutase at immediately post-tracheal intubation, hydrogen peroxide at 1 hour post-intubation, and 8-isoprostane at immediately post-surgical procedure were significantly higher in the high group than in the low group. The S100B levels at immediately post-surgical procedure were higher than those at immediately post-tracheal intubation and 1 hour post-intubation within the low group. Therefore, we conclude that inhaling a high concentration of oxygen during laparoscopic pyeloplasty under general anesthesia, for a duration of less than 3 hours, does not significantly increase oxidative stress in pediatric patients. This study was registered at the Chinese Clinical Trial Registry (registration No. ChiCTR2400083143).</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"15 2","pages":"332-338"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sevoflurane and its metabolic byproduct compound A induce nephrotoxicity: a systematic review and meta-analysis of animal studies.","authors":"Intek Hong, Kevin D Bigam, Brie M McConnell, Timur J P Özelsel, Rakesh V Sondekoppam","doi":"10.4103/mgr.MEDGASRES-D-24-00080","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00080","url":null,"abstract":"<p><p>Animal models investigating sevoflurane or compound A and renal function serve as the initial basis for concerns regarding renal injury following sevoflurane anesthesia and subsequent recommendations of minimum fresh gas flow, but this evidence basis has not been critically appraised. Primary literature searches were performed in MEDLINE OVID, PubMed, EMBASE, the Cochrane Library), the Cochrane Central Register of Controlled Trials, the International HTA Database, CINAHL, and Web of Science to identify randomized controlled trials and quasi-experimental studies in animals utilizing sevoflurane or compound A. The primary outcomes included renal function as determined by blood urea nitrogen, serum creatinine, creatinine clearance, and urine volume. The secondary outcomes included the serum fluoride concentration and histopathological findings. A total of 2537 records were screened, and 21 randomized controlled trials and 9 quasi-experimental animal studies were identified. No associations between sevoflurane exposure and subsequent changes in renal function (blood urea nitrogen, serum creatinine or changes in urine volume) were noted. A similar effect on renal function was observed following compound A exposure, but urine volume was elevated following compound A exposure. In addition, the histopathological damage following compound A exposure was observed only at concentrations that are unachievable in clinical practice. Our review of evidence from animal models revealed that sevoflurane usage was not associated with changes in renal function tests or urine volume. Histopathologic changes after sevoflurane exposure were either nonexistent or minor. Studies on compound A did not reveal an alteration in renal function, although histopathological evidence of injury was present when compound A was administered at very high, unphysiologic concentrations. In light of the existing evidence, the initial concerns of sevoflurane-related nephrotoxicity based on animal studies that leads to minimum fresh gas flow recommendations are called into question.</p>","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"15 2","pages":"254-265"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct generation of 1O2 in living tissues for the treatment of brain diseases.","authors":"Oxana Semyachkina-Glushkovskaya","doi":"10.4103/mgr.MEDGASRES-D-24-00092","DOIUrl":"10.4103/mgr.MEDGASRES-D-24-00092","url":null,"abstract":"","PeriodicalId":18559,"journal":{"name":"Medical Gas Research","volume":"15 2","pages":"208-209"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11918478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}